肝脏TM6SF2激活抗肿瘤免疫抑制代谢功能障碍相关脂肪性肝病相关肝细胞癌并增强免疫治疗
该研究在小鼠MASLD-HCC模型中证实,肝脏TM6SF2通过直接结合IKKβ抑制NF-κB信号通路减少IL-6分泌,从而激活细胞毒性CD8+ T细胞并抑制肿瘤形成;腺病毒导入Tm6sf2可改善小鼠MASLD-HCC的免疫治疗反应。
要点
- TM6SF2在MASLD-HCC患者肿瘤中较癌旁正常组织下调。
- 肝细胞特异性Tm6sf2敲除促进小鼠MASLD-HCC肿瘤形成,过表达则相反。
- TM6SF2通过NF-κB-IL-6轴激活细胞毒性CD8+ T细胞,腺病毒导入Tm6sf2改善小鼠免疫治疗反应。
核心结论
- 肝脏TM6SF2通过NF-κB-IL-6轴保护机体抵抗MASLD-HCC并激活细胞毒性CD8+ T细胞。
- TM6SF2是使MASLD-HCC对免疫治疗增敏的有前景策略。
研究设计与样本
- 研究采用肝细胞特异性Tm6sf2敲除(Tm6sf2 ∆hep)小鼠,分别喂食高脂/高胆固醇(HFHC)饮食或二乙基亚硝胺加HFHC饮食诱导MASLD-HCC。
- 研究还在原位MASLD-HCC小鼠中评估TM6SF2功能。
- 研究纳入人类MASLD-HCC标本评估临床意义。
主要发现
- TM6SF2在MASLD-HCC患者肿瘤中较癌旁正常组织下调。
- 肝细胞特异性Tm6sf2敲除在饮食诱导或饮食加致癌物诱导的MASLD-HCC小鼠中加剧肿瘤形成。
- Tm6sf2敲除的促肿瘤效应在原位MASLD-HCC小鼠中得到验证,而携带Tm6sf2过表达肿瘤的小鼠表型相反。
- 在Tm6sf2 ∆hep小鼠和原位Tm6sf2敲除小鼠的肿瘤中观察到干扰素-γ(IFN-γ)+CD8+ T细胞减少,而清除CD8+ T细胞后Tm6sf2的抑瘤效应消失。
- TM6SF2与CD8+ T细胞的相关性在人类MASLD-HCC组织中得到确认,提示TM6SF2可促进抗肿瘤免疫。
关键数值与推荐
- 机制上,TM6SF2直接结合IKKβ并抑制NF-κB信号通路以减少白细胞介素(IL)-6分泌,从而激活细胞毒性CD8+ T细胞。
- IL-6中和消除了Tm6sf2敲除在小鼠中的促肿瘤和免疫抑制效应。
- 通过腺病毒导入Tm6sf2改善了小鼠MASLD-HCC的免疫治疗反应。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transmembrane 6 superfamily member 2 (TM6SF2) has a protective role against metabolic dysfunction-associated steatotic liver disease (MASLD). OBJECTIVE: We aim to investigate the mechanistic role and therapeutic potential of hepatic TM6SF2 in MASLD-related hepatocellular carcinoma (HCC). DESIGN: Hepatocyte-specific Tm6sf2 knockout (Tm6sf2 ∆hep) mice were fed with high-fat/high-cholesterol (HFHC) diet or diethylnitrosamine plus HFHC diet to induce MASLD-HCC. TM6SF2 function was also evaluated in orthotopic MASLD-HCC mice. Human MASLD-HCC specimens were included to evaluate clinical significance. RESULTS: TM6SF2 was downregulated in tumours compared with adjacent normal tissues from MASLD-HCC patients. Hepatocyte-specific Tm6sf2 knockout exacerbated tumour formation in mice with diet-induced or diet-induced and carcinogen-induced MASLD-HCC. The tumour-promoting effect of Tm6sf2 knockout was verified in orthotopic MASLD-HCC mice, while mice bearing Tm6sf2-overexpressing tumours had opposite phenotypes. We observed the reduction of interferon-gamma (IFN-γ)+CD8+ T cells in the tumours of Tm6sf2 ∆hep mice and orthotopic Tm6sf2 knockout mice, while the tumour-suppressive effect of Tm6sf2 was abolished after depleting CD8+ T cells. The correlation between TM6SF2 and CD8+ T cells was confirmed in human MASLD-HCC tissues, inferring that TM6SF2 could promote antitumour immunity. Mechanistically, TM6SF2 directly bound to IKKβ and inhibited NF-κB signalling pathway to reduce interleukin (IL)-6 secretion, thereby activating cytotoxic CD8+ T cells. IL-6 neutralisation abolished the tumour-promoting and immunosuppressive effects of Tm6sf2 knockout in mice. Moreover, introducing Tm6sf2 by adenovirus improved immunotherapy response against MASLD-HCC in mice. CONCLUSION: Hepatic TM6SF2 protects against MASLD-HCC and activates cytotoxic CD8+ T cells via NF-κB-IL-6 axis. TM6SF2 is a promising strategy for sensitising MASLD-HCC to immunotherapy.
引用
- Zhang Y, Xie M, Wen J, et al. Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy. Gut. 2025. PMID: 39667906. doi:10.1136/gutjnl-2024-333154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。